| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CRISPR Therapeutics AG$53.35
-2.95 (-5.24%)
C 46Pipeline Score Overvalued Biotech · Clinical
Market Cap
4.86 B
EPS
-6.21
P/E Ratio
-
Value Trade
65.65 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.46 M
R&D Expenses
68.57 M
Operating CF
-108.90 M
Total Assets
2.73 B
Total Liabilities
911.26 M
Equity
1.81 B
D/E Ratio
12,345
1.25 %
Week
-10.99 %
1 Month
-6.8 %
3 Month
3.88 %
6 Month
-56.94 %
5 Year
235.73 %
All Time
Cash Data
Cash Position
2.44 B
Monthly Burn
36.30 M
Runway
65.3 mo
Burn Trend
SEC Filing
May 4, 2026
Overview
Volume
2.07 M
52 Week Range
35.38 - 78.48
% held by Insiders
7.16 %
% held by Institutions
72.81 %
Enterprise Value
3.20 B
Total Shares
95.95 M
Short %
24.66 %
Float Shares
82.71 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CRISPR Therapeutics AG
508Total events
2Upcoming
115Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
Event history 506
Q3 2026
◆Topline ReadoutCTX310Clinical Data
Update on CTX310 Phase 1b expected in H2 2026
severe hypertriglyceridemia, refractory hypercholesterolemiasource ↗
Q3 2026
◆Topline ReadoutCTX611Clinical Data
Update on CTX611 Phase 2 in TKA expected in H2 2026
thromboembolic disease (total knee arthroplasty)source ↗
Q3 2026
◆Topline Readoutzugo-celClinical Data
Update on zugo-cel in B-cell malignancies expected in H2 2026
B-cell malignanciessource ↗
Jun 2026
▲Trial InitiationCTX460Trial
Initiation of clinical trial for CTX460 expected in mid-2026
alpha-1 antitrypsin deficiency (AATD)source ↗
May 12, 2026
◆Oral PresentationPresentation
Presentation at Bank of America Securities 2026 Global Healthcare Conference
May 4, 2026
▲FDA Filing AcceptedCASGEVYApprovedRegulatory Filing
Vertex completed U.S. regulatory submission for CASGEVY in children ages 5 to 11
sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) in children ages 5 to 11source ↗
May 4, 2026
▲IND ClearanceCTX310IND
FDA clearance of IND for CTX310 supporting expansion into U.S.
severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemiasource ↗
May 4, 2026
▲IND Clearancezugo-celIND
FDA cleared IND for third Phase 1 trial of zugo-cel in autoimmune neurologic diseases
autoimmune neurologic diseases (PMS, NMOSD, MOGAD, AIE, SPS)source ↗
May 4, 2026
▲Trial Initiationzugo-celTrial
Phase 1 trial of zugo-cel in autoimmune neurologic diseases initiated
autoimmune neurologic diseasessource ↗
Apr 13, 2026
◆Oral PresentationPresentation
CRISPR Therapeutics management to present at 25th Annual Needham Virtual Healthcare Conference
Q2 2026
◆Trial InitiationCTX460Trial
Expected to initiate clinical trial in mid-2026
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
Drug Pipeline Intelligence
C46
Pipeline Score $798M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 68%
Small Cap (rank 293 of 911)
Percentile RankCRISPR Therapeutics AG carries a moderate pipeline score (46/100), with $1.2B risk-adjusted pipeline value, led by CTX310 in Cardiovascular (Phase 1), across $165B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX310 Small molecule | Cardiovascular | Phase 1 | NCT07491172 | 14% | $1.1B | RECRUITING | 90 | AVERAGE | D (28) | Jun 1, 2028 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
zugocaptagene geleucel | autoimmune diseases and hematologic malignancies | Phase 1 | 2025-12-22 | deep B-cell depletion sustained for at least 28 days; significant clinical improvement in patients dosed at the 100 million cell dose; first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6; overall response rate (ORR) of 90% (9/10); complete response rate (CRR) of 70% (7/10); 67% (2/3) of patients in complete response (CR) after one year on study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Read More | CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies Read More | |
zugocaptagene geleucel | autoimmune diseases and hematologic malignancies | Phase 1 | 2025-12-22 | deep B-cell depletion sustained for at least 28 days; significant clinical improvement in patients dosed at the 100 million cell dose; first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6; overall response rate (ORR) of 90% (9/10); complete response rate (CRR) of 70% (7/10); 67% (2/3) of patients in complete response (CR) after one year on study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Read More | CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies Read More | |
zugocaptagene geleucel | autoimmune diseases and hematologic malignancies | Phase 1 | 2025-12-22 | deep B-cell depletion sustained for at least 28 days; significant clinical improvement in patients dosed at the 100 million cell dose; first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6; overall response rate (ORR) of 90% (9/10); complete response rate (CRR) of 70% (7/10); 67% (2/3) of patients in complete response (CR) after one year on study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Read More | CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRSP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRSP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRSP▲ +5.3%on this news
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Read more →CRSP▲ +5.2%on this news
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
CRISPR Therapeutics announced that its senior management will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026. The presentation will include a live webcast, which will be available on the company's website. CRISPR Therapeutics is known for its pioneering work in gene editing and has a diverse pipeline of therapies.
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
CRISPR Therapeutics announced its Q1 2026 financial results, highlighting strong revenue from CASGEVY and advancements in its gene editing pipeline. The company expanded its treatment indications and received FDA clearance for pediatric use of CASGEVY. Despite a net loss of $122.9 million, CRISPR remains optimistic about its future milestones and market potential.
Read more →CRSPCRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The presentation will feature members of the senior management team and will be available via a live webcast. The company is recognized for its pioneering work in gene-based medicines, including the approval of the first CRISPR therapy for sickle cell disease.
Read more →CRSP▼ -5.4%on this news
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
Read more →CRSP▼ -10.2%on this newsshared move
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering ZUG, Switzerland and BOSTON
CRISPR Therapeutics has announced a proposed offering of $350 million in convertible senior notes due 2031, intended for qualified institutional buyers under Rule 144A. The offering includes an option for purchasers to acquire an additional $52.5 million of notes. Proceeds from the offering are aimed at general corporate purposes, although the specific interest rate and terms remain to be finalized. Investors may face uncertainties as the offering's success hinges on market conditions.
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results ZUG, Switzerland and BOSTON
CRISPR Therapeutics announced its financial results for Q4 and the full year 2025, highlighting significant progress in various clinical and preclinical programs. The revenue from CASGEVY reached $116 million for the year, with notable increases in patient initiation rates. Encouraging data from pediatric studies of CASGEVY were presented at the ASH annual meeting, supporting future regulatory submissions expected in 2026. Furthermore, the company's strong cash position enhances its ability to support ongoing and future development activities.
Read more →CRSPCRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
CRISPR Therapeutics has outlined its strategic priorities and key milestones for 2026, emphasizing a robust portfolio in gene editing and siRNA therapies. The company is well-positioned with a strong financial foundation and promising clinical data, particularly for its lead programs like CASGEVY and CTX310. Anticipated advancements in various therapeutic areas, including cardiovascular and autoimmune diseases, are expected to drive growth.
Read more →CRSPCRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will feature insights from the senior management team and will be available via live webcast. The company is recognized for its pioneering work in gene editing and has made significant advancements, including the approval of the first CRISPR-based therapy.
Read more →CRSPCRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
CRISPR Therapeutics has provided updates on zugocaptagene geleucel (zugo-cel), showing promising results in autoimmune diseases and hematologic malignancies. Initial data indicates deep B-cell depletion and clinical improvement in patients with systemic lupus erythematosus. A Phase 1 trial has been initiated for additional autoimmune conditions, and a collaboration with Lilly aims to evaluate zugo-cel in aggressive B-cell lymphomas.
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
CRISPR Therapeutics reported strong progress in its third quarter 2025 results, highlighting positive Phase 1 data for CTX310 and significant momentum for CASGEVY, with nearly 300 patient referrals. The company completed enrollment in two global Phase 3 studies for exa-cel and is advancing its pipeline, including ongoing clinical trials for CTX112 and SRSD107. With a robust financial position, CRISPR is well-positioned for future growth.
Read more →CRSPCRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
CRISPR Therapeutics announced positive Phase 1 clinical data for CTX310, showing significant reductions in ANGPTL3, triglycerides, and LDL cholesterol. The treatment was well tolerated, with no serious adverse events reported. These findings suggest CTX310 could offer a transformative approach for patients with severe dyslipidemia, advancing into Phase 1b trials.
Read more →CRSPCRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
CRISPR Therapeutics presented promising preclinical data for CTX460, a novel gene editing candidate targeting Alpha-1 Antitrypsin Deficiency (AATD), at the ESGCT 2025 Annual Congress. The data indicated over 90% mRNA correction and a significant increase in AAT levels. CTX460 is expected to enter clinical trials in mid-2026, marking a potential breakthrough in treating AATD.
Read more →CRSPCRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
CRISPR Therapeutics announced the acceptance of an abstract for an oral presentation at the ESGCT 2025 Annual Congress. The presentation will showcase their SyNTase gene editing technology, which demonstrated high efficiency in correcting Alpha-1 Antitrypsin Deficiency (AATD) with minimal off-target effects. The results indicate a promising potential for a single-dose treatment for this rare genetic disorder.
Read more →CRSPCRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
CRISPR Therapeutics and Sirius Therapeutics have initiated a Phase 2 clinical trial for SRSD107, a long-acting Factor XI siRNA aimed at preventing venous thromboembolism in patients undergoing total knee arthroplasty. The trial's first patient has been dosed, marking a significant milestone. SRSD107 aims to provide a safer alternative to existing anticoagulants by minimizing bleeding risks while effectively managing thrombotic conditions.
Read more →CRSPCRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025
CRISPR Therapeutics will present late-breaking data on its investigational gene editing therapy CTX310 at the AHA Scientific Sessions 2025. The presentation will highlight Phase 1 clinical data targeting ANGPTL3 for cardiovascular diseases. Additionally, a poster presentation on CTX340, aimed at treating refractory hypertension, will also be featured.
Read more →CRSP▲ +6.2%on this news
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results -CASGEVY momentum building; 75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 pat
CRISPR Therapeutics has reported strong momentum in its commercial and clinical programs, particularly with the authorization of over 75 treatment centers for CASGEVY. Preliminary data from the ongoing CTX310 trial shows significant reductions in triglycerides and LDL cholesterol. The company maintains a robust financial position with $1.7 billion in cash, supporting further development. Updates on several clinical trials are expected throughout 2025 and into 2026, indicating potential for future growth and patient impact.
Read more →CRSPCRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025
CRISPR Therapeutics has been named to TIME's 100 Most Influential Companies list for 2025, recognized in the Pioneers category for its advancements in gene editing. The company is noted for its expansion into treating cardiovascular and autoimmune diseases, beyond its initial successes with sickle cell disease and beta thalassemia. CEO Samarth Kulkarni highlighted the company's mission to transform medicine through innovation.
Read more →CRSPCRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
CRISPR Therapeutics has reported promising Phase 1 data for CTX310, showing dose-dependent reductions in triglycerides and LDL cholesterol. The company anticipates presenting complete data at a medical meeting in late 2025. Additionally, updates on CTX320 and CTX340 indicate continued progress in their cardiovascular pipeline.
Read more →CRSPCRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
Read more →CRSP▼ -11.9%on this news
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310 Targeting ANGPTL3 -Initial CTX310 Phase 1 clinical data demonstrates dose-depen
CRISPR Therapeutics reported its financial results for Q1 2025 alongside positive top-line data from its Phase 1 trial of CTX310, which targets ANGPTL3. The data demonstrated significant reductions in triglycerides and LDL cholesterol among patients, indicating the potential effectiveness of the therapy. Furthermore, the company highlighted progress in its pipeline and expansion efforts with CASGEVY, with over 65 treatment centers activated globally. The firm remains optimistic about upcoming data updates and its strong cash position supports ongoing developments.
Read more →CRSPCRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Read more →CRSPCRISPR Therapeutics Announces Transition of Chief Operating Officer ZUG, Switzerland and BOSTON
CRISPR Therapeutics announced the resignation of Chief Operating Officer Julianne Bruno, effective April 11, 2025. Over the past six years, Bruno played a crucial role in advancing the company's hematology and oncology programs. Her leadership was pivotal in maturing the operating model and driving several key initiatives. The company continues to position itself as a leader in the gene-based medicines sector, with a broad portfolio of product candidates targeting serious diseases.
Read more →CRSPCRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results -2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY
CRISPR Therapeutics has provided a business update reporting positive developments for the fourth quarter and full year 2024, highlighting an exciting 2025 ahead with several key milestones across its programs. The ongoing launch of the gene therapy CASGEVY is gaining momentum, with over 50 authorized treatment centers activated globally and anticipated growth in new patient collections. The company also announced strategic partnerships and clinical trials for multiple next-generation CAR T and gene editing therapies. Overall, CRISPR Therapeutics remains committed to advancing its innovative treatments for serious diseases.
Read more →CRSPCRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
Read more →CRSPCRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Read more →CRSPCRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Read more →CRSPCRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
Read more →CRSPCRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
Read more →CRSP▼ -5.9%on this news
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
Read more →CRSPCRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results -CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-depen
CRISPR Therapeutics has reported positive developments in its pipeline and financial results for Q3 2024, highlighting the approval of CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia in Switzerland and Canada. The company now has 45 activated treatment centers worldwide and is progressing with ongoing clinical trials for several next-generation CAR T product candidates. Additionally, CRISPR Therapeutics boasts a robust financial position with nearly $1.9 billion in liquid assets. Future updates on clinical trial outcomes are anticipated, particularly at the upcoming American Society of Hematology Annual Meeting.
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 20 patients have had cells
CRISPR Therapeutics reported its second quarter 2024 financial results, highlighting the activation of over 35 treatment centers for CASGEVY, which has been approved in several regions for treating sickle cell disease and beta thalassemia. The company is advancing multiple clinical trials for its next-generation CAR T therapies, CTX112 and CTX131, targeting various indications including autoimmune diseases. Additionally, CRISPR Therapeutics maintains a robust balance sheet with around $2 billion in liquid assets, positioning it well for future developments. The company is also focused on innovative approaches in gene editing and regenerative medicine.
Read more →CRSPCRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
Read more →CRSPCRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
Read more →CRSPCRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results — More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY and multiple patients have already ha
CRISPR Therapeutics announced a strong business update along with its financial results for Q1 2024, highlighting the activation of over 25 authorized treatment centers for its therapy CASGEVY. The company is advancing clinical trials for next-generation CAR T product candidates and in vivo gene editing therapies. Additionally, CRISPR Therapeutics is expanding its pre-clinical pipeline with new programs targeting various health conditions and maintaining a strong financial position with a cash reserve of approximately $2.1 billion. The CEO emphasized the potential for broadening patient access to their gene-editing therapies in the near future.
Read more →CRSPCRISPR Therapeutics to Present Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting
Read more →CRSPCRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
Read more →CRSPCRISPR Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting
CRISPR Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results — CASGEVY approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain &
CRISPR Therapeutics has reported significant advancements and financial results for 2023, highlighting the approval of CASGEVY, the first CRISPR-based therapy, across several regions including the U.S. and the EU. The company is actively pursuing clinical trials for next-generation CAR T therapies and in vivo gene editing programs with potential applications in several serious conditions. Additionally, its strong financial position, bolstered by a $280 million offering, positions CRISPR well for future developments. Looking ahead, CRISPR Therapeutics aims to continue expanding its pipeline and initiating new clinical trials.
Read more →CRSP▲ +6.9%on this newsshared move
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
Read more →CRSPEuropean Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Read more →CRSPCRISPR Therapeutics Announces $280 Million Registered Direct Offering
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
Read more →CRSPCRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
Read more →CRSPCRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
Read more →CRSP▼ -5.3%on this newsshared move
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read more →CRSP▼ -8.1%on this news
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Read more →CRSPCRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
Read more →CRSP▲ +5.3%on this news· ran to +21% by day 1
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Read more →CRSPCRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Read more →CRSP▲ +12.4%on this news· ran to +32% by day 3shared move
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
Read more →CRSP▲ +12.4%on this news· ran to +32% by day 3shared move
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
Read more →CRSP▲ +12.4%on this news· ran to +32% by day 3shared move
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results -Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) compl
CRISPR Therapeutics recently provided a business update and reported its third quarter 2023 financial results. The company is focused on the upcoming FDA review, with a PDUFA date set for exa-cel, which aims to treat severe sickle cell disease, highlighting its potential as the first CRISPR-based therapy available in the U.S. Various ongoing clinical trials for multiple therapies demonstrate the company's broad commitment to advancing gene-based medicines. However, the financial report revealed a decrease in cash reserves compared to the previous quarter, although the company remains well-capitalized for future developments.
Read more →CRSPCRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Read more →CRSPCRISPR Therapeutics Announces Leadership Transition -CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective
CRISPR Therapeutics has announced a leadership change, with co-founder Rodger Novak, M.D., stepping down as President and Chairman effective September 15, 2023. Samarth Kulkarni, Ph.D., who currently serves as CEO, will succeed him in the chairman role. Novak has played a significant role in the company’s development for nearly a decade, guiding its business model, collaboration efforts, and IPO. The company is optimistic about its future as it nears potential regulatory approval for its investigational therapy, exa-cel.
Read more →CRSPCRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
Read more →CRSP▼ -5.1%on this news
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results - FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (S
CRISPR Therapeutics has announced that the FDA accepted Biologics License Applications for exagamglogene autotemcel (exa-cel) aimed at treating severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia. The company reported positive phase trial results that indicate substantial benefits for patients. With ongoing enrollment in various clinical trials, CRISPR Therapeutics remains well-positioned to advance multiple gene therapies. Financial results for the second quarter of 2023 have also been disclosed, indicating continued positive momentum for the firm.
Read more →CRSPCRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
Read more →CRSPFDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - First CRISPR gene-editing filings to be accepted for review by
The FDA has accepted the Biologics License Applications for exagamglogene autotemcel (exa-cel), a pioneering CRISPR gene-editing therapy aimed at severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The therapy received Priority Review designation for SCD and Standard Review status for TDT, with target action dates set for December 8, 2023, and March 30, 2024, respectively. Vertex Pharmaceuticals and CRISPR Therapeutics continue to advance the therapy in clinical trials, with updated data to be presented soon at the EHA Congress.
Read more →CRSPPositive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001 , in the U.S. for transfusio
CRISPR Therapeutics announced a business update detailing significant progress across its portfolio, particularly the completion of regulatory submissions for exagamglogene autotemcel (exa-cel) in multiple jurisdictions. The company is positioned to potentially introduce the first CRISPR-based therapy while also advancing several clinical trials for new CAR T cell therapies. Their strong financial position, with approximately $1.889 billion in cash and collaborations expected to generate more revenue in the coming months, further supports their objectives. The company remains focused on innovative treatments for serious diseases including T cell lymphomas and type 1 diabetes.
Read more →CRSPCRISPR Therapeutics to Participate Upcoming Investor Conferences
CRISPR Therapeutics to Participate Upcoming Investor Conferences
Read more →CRSP▲ +16.3%on this news
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
Read more →CRSPCRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Read more →CRSPVertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -EU and UK
Vertex Pharmaceuticals and CRISPR Therapeutics have completed the submission of rolling Biologics License Applications (BLAs) to the FDA for their gene-editing therapy exagamglogene autotemcel (exa-cel), aimed at treating sickle cell disease and transfusion-dependent beta thalassemia. The submissions include requests for Priority Review, potentially reducing FDA review time. Exa-cel, which has shown positive results in ongoing Phase 3 trials, has also been granted various designations to facilitate its regulatory pathway in both the U.S. and Europe.
Read more →CRSPCRISPR Therapeutics Announces Departure of Board Member ZUG, Switzerland and Boston, Mass.
CRISPR Therapeutics has announced the departure of Brad Bolzon from its Board of Directors after nearly ten years. Bolzon played a critical role in shaping the company's strategy and success, contributing extensively to its development since its inception. Both the President, Rodger Novak, and the CEO, Samarth Kulkarni, expressed gratitude for his leadership and ongoing support throughout his tenure. Bolzon himself acknowledged the accomplishments of the leadership team and expressed confidence in their continuing success.
Read more →CRSPVertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes -Vertex to receive non-exclusive rights to CRISPR Therapeut
Vertex Pharmaceuticals and CRISPR Therapeutics have established a non-exclusive licensing agreement to enhance Vertex's hypoimmune cell therapies aimed at treating Type 1 Diabetes (T1D). Under this agreement, Vertex will pay CRISPR $100 million upfront, along with potential milestones and royalties for future products. Vertex aims to develop insulin-producing hypoimmune islet cells through this collaboration. This partnership is expected to accelerate the progress of Vertex's T1D programs, particularly VX-880 and VX-264, which are currently in clinical trials.
Read more →CRSPCRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
Read more →CRSPCRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
Read more →CRSP▲ +5.8%on this newsshared move
CRISPR Therapeutics Announces Transition of Chief Financial Officer ZUG, Switzerland and Boston, Mass.
CRISPR Therapeutics has appointed Dr. Raju Prasad as its new Chief Financial Officer, effective March 14, 2023. Dr. Prasad previously worked at William Blair & Company, where he specialized in cell therapy and gene therapy research. He succeeds Brendan Smith, who is leaving to pursue other opportunities. The CEO emphasized Dr. Prasad's depth of knowledge and experience in the biotechnology sector, expressing optimism about the future of the company under his financial leadership.
Read more →CRSPCRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
Read more →CRSP▼ -8.4%on this news
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent bet
CRISPR Therapeutics announced significant progress in its clinical programs with complete regulatory submissions for exagamglogene autotemcel (exa-cel) in Europe and ongoing U.S. submissions. The company is advancing its pipeline, which includes CAR T therapies CTX110, CTX130, and the new CTX112 and CTX131 targeting various malignancies. Additionally, they have initiated clinical trials for the diabetes treatment VCTX211 and expect to begin trials for CTX310, an in vivo gene editing candidate. The positive financial results reflect the company's commitment to transforming gene-based medicines for serious diseases.
Read more →CRSPCRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
Read more →CRSP▼ -5.1%on this news
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
Read more →CRSPCRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
Read more →CRSPCRISPR Therapeutics and Vertex to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
CRISPR Therapeutics and Vertex to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
Read more →CRSPCRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
Read more →CRSP▲ +11.8%on this news· ran to +25% by day 3
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Read more →CRSPCRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results -Exagamglogene autotemcel (exa-cel), formerly known as CTX001 submission to the U.S. Food and Drug Administration (FDA) for ro
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results -Exagamglogene autotemcel (exa-cel), formerly known as CTX001 submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion
Read more →CRSP▼ -5.1%on this newsshared move
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer ZUG, Switzerland and BOSTON, Mass. –
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer ZUG, Switzerland and BOSTON, Mass. October 27, 2022 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today
Read more →CRSPCRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Read more →CRSPCRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
Read more →CRSP▲ +5.2%on this newsshared move
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
Read more →CRSPVertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, wit
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 -Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 -EMA
Read more →CRSPCRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
CRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results -CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly kn
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results -CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001 , with the European Medicines Agency (EMA) an
Read more →CRSP▼ -7.6%on this news
The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements
CRISPR Therapeutics Innovation Day June 21, 2022 Exhibit 99.1 The presentation and other related materials may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CR
Read more →CRSP▼ -13.3%on this news
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress - Data from 75 patients wi
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress - Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle
Read more →CRSP▼ -13.3%on this news
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
Read more →CRSP▲ +6.9%on this news· ran to -20% by day 3shared move
CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Read more →CRSP▲ +5.4%on this news· ran to +19% by day 3
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
Read more →CRSPCRISPR Therapeutics to Host Innovation Day on June 21, 2022
CRISPR Therapeutics to Host Innovation Day on June 21, 2022
Read more →CRSPCRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer ZUG, Switzerland and
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicin
Read more →CRSP▲ +6.6%on this news· ran to +24% by day 3shared move
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130 for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130 for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress ZUG, Switzerland and CAMBRIDGE, Mass. May 12, 2022 -- (GLO
Read more →CRSP▼ -10%on this newsshared move
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results - More than 75 patients dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissio
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results - More than 75 patients dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase
Read more →CRSP▲ +5.7%on this news· ran to -18% by day 3shared move
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
Read more →CRSP▲ +9.3%on this news
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - More than 70 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - More than 70 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022-
Read more →CRSP▲ +6.6%on this news
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Read more →CRSP▼ -5.2%on this news
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
Read more →CRSPCRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110 for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies ZUG, Switzerland and
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110 for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies ZUG, Switzerland and CAMBRIDGE, Mass., November 22, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biop
Read more →CRSPCRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results -Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory sub
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results -Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late 2022- -Reported positive results
Read more →CRSPCRISPR Therapeutics Announces Transition of Chief Financial Officer ZUG, Switzerland and
CRISPR Therapeutics Announces Transition of Chief Financial Officer ZUG, Switzerland and CAMBRIDGE, Mass. October 14, 2021 (GLOBE NEWSWIRE) CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas
Read more →CRSPCRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110 in Relapsed or Refractory CD19+ B-cell malignancies -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cel
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis-
Read more →CRSPCRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
Read more →CRSPCRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Read more →CRSPCRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference
CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference
Read more →CRSP▲ +7.1%on this news
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results - More than 45 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results - More than 45 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021- -Received Orphan Drug
Read more →CRSPCRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
Read more →CRSPVertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at European Hematology Association Annual M
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at European Hematology Association Annual Meeting - Beta thalassemia: All 15 patients were transfusion
Read more →CRSPVertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
Read more →CRSPCRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
Read more →CRSPCRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results - Granted Priority Medicines designation by the European Medicines Agency for CTX001 for transfusion-dependent beta thalassemi
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results - Granted Priority Medicines designation by the European Medicines Agency for CTX001 for transfusion-dependent beta thalassemia (TDT)- -More than 30 patients have been dosed with CTX00
Read more →CRSPVertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Read more →CRSPVertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia - Under terms of amended agreement, Vertex to
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercializa
Read more →CRSPCRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
Read more →CRSPCRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
Read more →CRSPCRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - More than 20 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results ZUG, Switzerland and CAMBRIDGE, Mass., February 16, 2021 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based m
Read more →CRSPCRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day
Read more →CRSPCRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer
CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer
Read more →CRSPCRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
Read more →CRSPCRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England J
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine - Beta thalassemia: All seven patients w
Read more →CRSPCRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Th
CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Th
Read more →CRSPCRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Read more →CRSPCRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
Read more →CRSPCRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition ZUG, Switzerland and CAMBRIDGE, Mass. and BO
CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, November 4, 2020 -- CRISPR Therapeutics (Nasdaq: CRSP
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results -Reported positive top-line results from the Company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX1
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results -Reported positive top-line results from the Company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110 , targeting CD19+ B-cell malignancies- - Received Rare
Read more →CRSPCRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110 in Relapsed or Refractory CD19+ B-cell Malignancies -50% (2/4) complete response (CR) rate at three months in the Dose Level 3
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110 in Relapsed or Refractory CD19+ B-cell Malignancies -50% (2/4) complete response (CR) rate at three months in the Dose Level 3 (DL3) cohort; both responders remain in CR- -Early eviden
Read more →CRSPCRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
Read more →CRSPCRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
Read more →CRSPCRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results -Dosing re-initiated in clinical trials of CTX001 for patients with severe hemoglobinopathies- - CTX001 has received orphan d
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results -Dosing re-initiated in clinical trials of CTX001 for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease
Read more →CRSPCRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
Read more →CRSPCRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES ZUG, Switzerland and
CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES ZUG, Switzerland and CAMBRIDGE, Mass., June 29, 2020 (GLOBE NEWSWIRE) CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious dis
Read more →CRSPCRISPR Therapeutics Announces Proposed Offering of Common Shares
CRISPR Therapeutics Announces Proposed Offering of Common Shares
Read more →CRSPCRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility
CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility
Read more →CRSPCRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001 in Severe Hemoglobinopathies at the 25 th Annual European Hematology Association (EHA) Congress -Beta thalassemia:
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001 in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress -Beta thalassemia: Two patients are transfusion independent at 5 and 15 months
Read more →CRSPCRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting
Read more →CRSPNew Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress ZUG, Switzerland and CAMBRIDGE,
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 -- CRISPR Therapeutics (Nas
Read more →CRSPCRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the Treatment of Severe Hemoglobinopathies - CTX001 has received Orphan Drug Des
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the Treatment of Severe Hemoglobinopathies - CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for tra
Read more →CRSPCRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results -Enrollment ongoing in clinical trials of CTX001 for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results -Enrollment ongoing in clinical trials of CTX001 for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110 , targeting CD19+ malignancies- -Began tr
Read more →CRSPCRISPR Therapeutics Proposes Changes to the Board of Directors ZUG, Switzerland and
CRISPR Therapeutics Proposes Changes to the Board of Directors ZUG, Switzerland and CAMBRIDGE, Mass., February 26, 2020 (GLOBE NEWSWIRE) CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results -Enrollment ongoing in clinical trials of CTX001 for patients with severe hemoglobinopathies- -Enrollment ongoi
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results -Enrollment ongoing in clinical trials of CTX001 for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110 , targeting CD19+ malignanc
Read more →CRSPCRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
Read more →CRSPCRISPR Therapeutics to Present at Upcoming Investor Conferences
CRISPR Therapeutics to Present at Upcoming Investor Conferences
Read more →CRSPCRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies -Two patients treated w
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies -Two patients treated with CTX001 successfully engrafted and demonstrated an init
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results -Provides update from ongoing Phase 1/2 clinical trials of CTX001 for patients with severe hemoglobinopathies- -Began treating
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results -Provides update from ongoing Phase 1/2 clinical trials of CTX001 for patients with severe hemoglobinopathies- -Began treating patients in Phase 1/2 clinical trial of CTX110 , targetin
Read more →CRSPCRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics
CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics
Read more →CRSPCRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
Read more →CRSPCRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019
CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results -Provides update in ongoing Phase 1/2 clinical trials of CTX001 for patients with severe hemoglobinopathies- -Enrolling in Ph
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results -Provides update in ongoing Phase 1/2 clinical trials of CTX001 for patients with severe hemoglobinopathies- -Enrolling in Phase 1/2 clinical trial of CTX110 , targeting CD19+ maligna
Read more →CRSPCRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes
CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes
Read more →CRSPVertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics -Provides Vertex with leading gene editing capa
Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics -Provides Vertex with leading gene editing capabilities to develop novel therapies for Duchenne Muscular
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results -Enrollment ongoing in Phase 1/2 clinical trials of CTX001 for patients with severe hemoglobinopathies- -IND and CTA approved
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results -Enrollment ongoing in Phase 1/2 clinical trials of CTX001 for patients with severe hemoglobinopathies- -IND and CTA approved for CTX110 , wholly-owned allogeneic CAR-T cell therapy ta
Read more →CRSPCRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia
Read more →CRSPCRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting
Read more →CRSPCRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 -First patient infused with CTX001 in a Phase 1/2 clinical trial for patie
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta -First patient enrolled in a Phase 1/2 clin
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First pat
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for
Read more →CRSPCRISPR Therapeutics Proposes New Members to the Board of Directors
CRISPR Therapeutics Proposes New Members to the Board of Directors
Read more →CRSPCRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement
CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement
Read more →CRSPCRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies
Read more →CRSPCRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease
Read more →CRSPCRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results - Initiated Phase 1/2 Clinical Trial of CTX001 in -thalassemia- -Targeting Initiation of Clinical Trial for CTX110, Targeting
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results -Initiated Phase 1/2 Clinical Trial of CTX001 in -thalassemia- -Targeting Initiation of Clinical Trial for CTX110, Targeting CD19+ Malignancies, in 1H 2019- -$487.3 Million in Cash as
Read more →CRSPCRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease ZUG, Switzerland and CAMBRIDGE and
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass., October 10, 2018 CRISPR Therapeutics (NASDAQ:CRSP), a biop
Read more →CRSPCRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference
CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference
Read more →CRSPCRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes - Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for
CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes - Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for diabetes - - Parties will collaborate through commercial
Read more →CRSPCRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology ZUG, Switzerland, CAMBRIDGE, M
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results -Obtained Approvals of CTAs in Multiple Countries for CTX001 in -thalassemia and SCD- -Initiation of Clinical Trials for CTX0
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results -Obtained Approvals of CTAs in Multiple Countries for CTX001 in -thalassemia and SCD- -Initiation of Clinical Trials for CTX001 in -thalassemia and SCD on Track for 2018- -Preclinic
Read more →CRSPCRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
Read more →CRSPCRISPR Therapeutics to Participate in Three June Conferences
CRISPR Therapeutics to Participate in Three June Conferences
Read more →CRSPCRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease Boston, MA, Zug, Switzerland and Cambridge, MA
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease Boston, MA, Zug, Switzerland and Cambridge, MA May 30, 2018 - CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals In
Read more →CRSPCRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results -On track to begin CTX001 clinical study in hemoglobinopathies in 2018- -On track to file IND in 2018 for CTX101, allogeneic C
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results -On track to begin CTX001 clinical study in hemoglobinopathies in 2018- -On track to file IND in 2018 for CTX101, allogeneic CRISPR-based CAR-T targeted toward CD19+ malignancies - -
Read more →CRSPCRISPR Therapeutics to Participate in May Investor Conferences
CRISPR Therapeutics to Participate in May Investor Conferences
Read more →CRSPCRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
Read more →CRSPCRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
Read more →CRSPCRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
Read more →CRSPCRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property
CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results - On track to begin first company-sponsored clinical trials of a CRISPR-based therapy - - Wholly-owned CRISPR-b
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results - On track to begin first company-sponsored clinical trials of a CRISPR-based therapy - - Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly - ZUG,
Read more →CRSPCRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
Read more →CRSPCRISPR Therapeutics Announces Transition of Bill Lundberg, MD
CRISPR Therapeutics Announces Transition of Bill Lundberg, MD
Read more →CRSPCRISPR Therapeutics Announces Proposed Public Offering of Common Shares ZUG, Switzerland and
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares ZUG, Switzerland and CAMBRIDGE, Mass. - January 3, 2018 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, toda
Read more →CRSPCRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board ZUG, Switzerland and
CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board ZUG, Switzerland and CAMBRIDGE, Mass. December 21, 2017 CRISPR Therapeutics (NASDAQ: CRSP) today announced the appointment of Dr. Rodger Novak, founder and former CEO of CRISPR Therapeutics a
Read more →CRSPVertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and -Thalassemia -Vertex selects CTX001 as first gene edited treatment to be developed
Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease -Vertex selects CTX001 as first gene edited treatment to be developed as part of collaboration with CRISPR Therapeutics- -Clinical Trial Applic
Read more →CRSPCRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting
Read more →CRSPCRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in -thalassemia -Phase 1/2 trial in - thalassemia expected to begin in 2018- Zug, Switzerland, Cambridge, MA
CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in -thalassemia -Phase 1/2 trial in -thalassemia expected to begin in 2018- Zug, Switzerland, Cambridge, MA December 7, 2017 - CRISPR Therapeutics (NASDAQ: CRSP) today announc
Read more →CRSPCRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting
Read more →CRSPCRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs
Read more →CRSPCRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer ZUG, Switzerland and
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer ZUG, Switzerland and CAMBRIDGE, Mass., November 13, 2017 CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious d
Read more →CRSPCRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting
CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting
Read more →CRSPCRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update - On track to begin first company-sponsored clinical trial of a CRISPR-based therapeutic - - Wholly-owned CRISPR-based CAR-T
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update - On track to begin first company-sponsored clinical trial of a CRISPR-based therapeutic - - Wholly-owned CRISPR-based CAR-T programs advancing rapidly - - New collaborations enhan
Read more →CRSPCRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32 nd Annual Society for Immunotherapy of Cancer Meeting ZUG, Switzerland and
CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting ZUG, Switzerland and CAMBRIDGE, Mass., November 7, 2017 CRISPR Therapeutics (NASDAQ: CRSP), a genome edit
Read more →CRSPCRISPR Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance to Collaborate with University of Alabama at Birmingham on Gene-edited Treatments for Friedrich’s Ataxia
CRISPR Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance to Collaborate with University of Alabama at Birmingham on Gene-edited Treatments for Friedrich’s Ataxia
Read more →CRSPCRISPR Therapeutics to Present at Investor Conferences in October
CRISPR Therapeutics to Present at Investor Conferences in October
Read more →CRSPCRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer Company President to assume CEO role effective
CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer Company President to assume CEO role effective December 1, 2017 ZUG, Switzerland and CAMBRIDGE, Mass., October 2, 2017 CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company
Read more →CRSPCRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies
CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies
Read more →CRSPCRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update On track to file for clinical trial application (CTA) for lead program in beta-thalassemia in 2017 Rapid progress in immuno
CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update On track to file for clinical trial application (CTA) for lead program in beta-thalassemia in 2017 Rapid progress in immuno-oncology including a lead program in allogeneic CAR-T ce
Read more →CRSPCRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development ZUG, Switzerland and
CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development ZUG, Switzerland and CAMBRIDGE, Mass., Aug 1, 2017 CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces t
Read more →CRSPCRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing
Read more →CRSPCONFIDENTIAL CLIA DRAFT FOR PLANNED RELEASE TUESDAY 25-JULY AT 4:30 PM EASTERN TIME CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Paten
CONFIDENTIAL CLIA DRAFT FOR PLANNED RELEASE TUESDAY 25-JULY AT 4:30 PM EASTERN TIME CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing ZUG, Switze
Read more →CRSPCRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration
CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration
Read more →CRSPCRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium
CRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium
Read more →CRSPCRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China Patent includes CRISPR/Cas9 gene editing methods and compositions for use in any non-cellular and cellular setting, including human and other eu
CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China BASEL, Switzerland, June 19, 2017 (GLOBE NEWSWIRE) CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced
Read more →CRSPCRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference
CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference
Read more →CRSPCRISPR Therapeutics Appoints James R. Kasinger as General Counsel CRISPR continues to add to the depth and breadth of its senior leadership team BASEL, Switzerland and
CRISPR Therapeutics Appoints James R. Kasinger as General Counsel CRISPR continues to add to the depth and breadth of its senior leadership team BASEL, Switzerland and CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical compan
Read more →CRSPCRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies
CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies
Read more →CRSPCRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress
CRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress
Read more →CRSPCRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS
CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS
Read more →CRSPCRISPR Therapeutics to Present at Investor Conferences in May
CRISPR Therapeutics to Present at Investor Conferences in May
Read more →CRSPCRISPR Therapeutics Reports Financial Results for the Three Months Ended
CRISPR Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Provides Business Update On track to file for clinical trial authorization (CTA) for lead program in beta-thalassemia in 2017 Expanded partnerships enhancing both ex vivo and in vivo de
Read more →CRSPCRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
Read more →CRSPCRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations Company to further strengthen senior leadership team at a critical phase in bring
CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations Company to further strengthen senior leadership team at a critical phase in bringing lead hemoglobinopathies programs into the clinic BAS
Read more →CRSPCRISPR Therapeutics to Present at the 42nd Annual Deutsche Bank Health Care Conference
CRISPR Therapeutics to Present at the 42nd Annual Deutsche Bank Health Care Conference
Read more →CRSPIntellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes CAMBRIDGE, Mass., Basel, Switzerland
Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes CAMBRIDGE, Mass., Basel, Switzerland, April 26, 2017, (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two le
Read more →CRSPCRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio
CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio
Read more →CRSPCRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision Appeal to the U.S. Court of Appeals for the Federal Circuit seeks review and reve
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board BASEL, Switzerland; CAMBRIDGE, Massachusetts; BERKELEY, California; DUBLIN, Ireland; April 13, 2017 (GLOBE NEWSWIRE) CRISPR Therapeutics (NASDAQ:CRS
Read more →CRSPCRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference
CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference
Read more →CRSPCRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing - Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic c
CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing - Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic cells BASEL, Switzerland, March 28, 2017 (GLOBE NEWSWIRE)
Read more →CRSPCRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte
Read more →CRSPCRISPR Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
CRISPR Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
Read more →CRSPCRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference
CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference
Read more →CRSPCRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation
CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation
Read more →CRSPCRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K. UC s patent application
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K. BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, California, DUBLIN, Ireland, Feb.
Read more →CRSPCRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents
CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents
Read more →CRSPCRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology BASEL, Switzerland, CAMBRIDGE,
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, California, DUBLIN, Ireland, December 16
Read more →CRSPCRISPR Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
CRISPR Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
Read more →CRSPCRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β-Thalassemia
CRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β-Thalassemia
Read more →CRSPCRISPR Therapeutics to Present at the Stifel 2016 Healthcare Conference
CRISPR Therapeutics to Present at the Stifel 2016 Healthcare Conference
Read more →CRSPCasebia Therapeutics Press Release: Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer
Casebia Therapeutics Press Release: Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer
Read more →CRSPCRISPR Therapeutics Announces Pricing of Initial Public Offering
CRISPR Therapeutics Announces Pricing of Initial Public Offering
Read more →CRSPCRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
Read more →CRSPCRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases
CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases
Read more →CRSPCRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise
CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise
Read more →CRSPCRISPR Therapeutics Strengthens Its Leadership Team with the Appointment of Marc Becker as Chief Financial Officer
CRISPR Therapeutics Strengthens Its Leadership Team with the Appointment of Marc Becker as Chief Financial Officer
Read more →CRSPBayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases
Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases
Read more →CRSPGénéthon and CRISPR Therapeutics announce Research Collaboration
Généthon and CRISPR Therapeutics announce Research Collaboration
Read more →CRSPCRISPR Therapeutics Appoints Tony Coles, M.D., to its Board of Directors
CRISPR Therapeutics Appoints Tony Coles, M.D., to its Board of Directors
Read more →CRSPVertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases
Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases
Read more →CRSPFierceBiotech names CRISPR Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
FierceBiotech names CRISPR Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
Read more →CRSPCRISPR Therapeutics Bolsters Management Team with Samarth Kulkarni as Chief Business Officer and Michael Bruce as Senior Vice President, Program Portfolio and Alliance Management
CRISPR Therapeutics Bolsters Management Team with Samarth Kulkarni as Chief Business Officer and Michael Bruce as Senior Vice President, Program Portfolio and Alliance Management
Read more →CRSPCRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients
CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients
Read more →CRSPCRISPR Therapeutics Congratulates Scientific Founder Dr. Emmanuelle Charpentier on Addition to TIME Magazine’s 100 Most Influential People and Award of Louis Jeantet Prize for Medicine
CRISPR Therapeutics Congratulates Scientific Founder Dr. Emmanuelle Charpentier on Addition to TIME Magazine’s 100 Most Influential People and Award of Louis Jeantet Prize for Medicine
Read more →CRSPCRISPR Therapeutics to Establish R&D Operations in Cambridge, Massachusetts
CRISPR Therapeutics to Establish R&D Operations in Cambridge, Massachusetts
Read more →CRSPCRISPR Therapeutics Founding Scientist, Emmanuelle Charpentier Awarded 2015 Breakthrough Prize in Life Sciences
CRISPR Therapeutics Founding Scientist, Emmanuelle Charpentier Awarded 2015 Breakthrough Prize in Life Sciences
Read more →CRSPCRISPR Therapeutics Raises $25 million in Series A Financing and Announces Founding Team of World-Renowned Academics and Clinicians
CRISPR Therapeutics Raises $25 million in Series A Financing and Announces Founding Team of World-Renowned Academics and Clinicians
Read more →Competitive Position
How CRSP ranks across every disease it competes inCompetitive Position is a premium feature
See how CRSP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial